CABOGEN is a Observational, retrospective, multicenter study that will enroll patients with metastatic clear cell renal carcinoma (mccRCC) treated with cabozantinib after one or more previous lines of treatment that included TKIs, immune checkpoint inhibitors or mTOR inhibitors.
Age ≥ 18 years.
Patients with histological diagnosis of predominantly clear cell carcinoma
Availability of the tumor tissue from the primary tumor and/or a metastatic site for the genomic profiling analysis not older than 5 years.
Evaluable disease according to RECIST criteria v 1.1
Non-availability of tumor tissue from the primary tumor or a metastatic site for biomarker analysis
Patient progressed between 3 and 9 months from the beginning of treatment with cabozantinib.
Non-availability of clinical information useful to evaluate the IMDC risk group at baseline.